| |
Wednesday, August 7, 2024 | 10am ET / 7am PT Demand for safe, cost-effective RNA manufacturing is increasing. Knowing how to effectively streamline processes and choose the right partners are critical to success. Join us as we explore the latest strategies and solutions to meet today’s increasing demands for safety and cost-effectiveness. Register now.
|
|
Today’s Big NewsJul 23, 2024 |
| By Darren Incorvaia After 14 years on the board of Moderna, the biotech that became a household name after developing an mRNA vaccine for Covid-19, chemical engineer Robert Langer, Sc.D., is retiring from the company’s board. |
|
|
|
By Joseph Keenan BeiGene continued its global expansion march with the opening of its flagship biologics manufacturing and R&D facility in Hopewell, New Jersey. |
By Nick Paul Taylor Sanofi has reached a critical milestone in its push to change how it is seen by the wider world. With the world’s media descending on Paris for the Olympics, the French drugmaker is ramping up for the “biggest corporate activation” in its history. |
By Conor Hale Named DORA, the manuscript helper taps multiple AI and large language models to support the drafting of academic papers and case studies, in addition to applications for grants and patents. |
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Secure your pass today!
|
|
By Annalee Armstrong Pinetree Therapeutics will help AstraZeneca plant some trees in its pipeline with a new pact to develop a preclinical EGFR degrader worth $45 million upfront for the small biotech. |
By Zoey Becker So far, the company has received one report of an adverse event stemming from the "potential presence" of a sedative inside the pain med's packaging. |
By Fraiser Kansteiner Earlier this month, Novo Nordisk purchased a 200-acre site in Odense, Denmark’s third largest city, the company has confirmed. Novo is now set to kick off preparatory excavation work for a potential new production plant. |
By Conor Hale Researchers quizzed an AI using four years’ worth of online image challenges from the New England Journal of Medicine—a long-running column that tests the reader’s ability to diagnose a patient, based on a series of submitted pictures and some basic clinical background information. |
By Ben Adams The life sciences industry continues to see a trend of rebranding as another biotech company decides to embrace change by saying goodbye to the old and welcoming the new. |
By Andrea Park Well, that was fast. Barely six months after Jay Carter announced his retirement following an illustrious 40-year career in healthcare and pharma marketing, he’s back in the saddle. |
By Kevin Dunleavy Pfizer has opened an extension to its active pharmaceutical ingredient (API) plant in Singapore. The SGD $1 billion ($743 million) project covers 429,000 square feet and will produce antibiotics and small molecules to treat cancer and pain, the company said. |
By Ben Adams The 30-plus-year pharma veteran Phil Tennant is stepping in to take on what could be one of the biggest challenges in life sciences: selling a new gene therapy from a small biotech. |
Fierce podcastsDon’t miss an episode |
| In February, Novo Holdings announced a $16.5 billion deal to acquire Catalent, and this week on "The Top Line," we explore the current state and implications of the proposed buyout. |
|
|---|
|
|
|
Wednesday, September 11, 2024 | 2pm ET / 11am PT As the drug development landscape rapidly evolves, artificial intelligence (AI) is emerging as a transformative force, fundamentally reshaping processes and enhancing efficiencies. Join us for a deep dive into AI’s significant impact on streamlining clinical project management, revolutionizing the generation of crucial research outputs and accelerating drug discovery. Register now.
|
|
| WhitepaperDownload the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
| WhitepaperIn this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
| WhitepaperIn a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
